Immutep announces patient enrollment completed for EFTISARC-NEO Phase II trial

Immutep (IMMP) announces that patient enrolment has been completed in the investigator-initiated EFTISARC-NEO trial. EFTISARC-NEO is evaluating eftilagimod alpha in combination with radiotherapy plus KEYTRUDA in the neoadjuvant setting for patients with resectable soft tissue sarcoma, STS. The Phase II trial conducted by the Maria Skodowska-Curie National Research Institute of Oncology in Warsaw, the national reference centre for STS in Poland, has reached its enrolment target of 40 patients.